News

On February 19, 2026, RingCentral will report its fourth‑quarter and full‑year 2025 results after the market close. A conference call will follow at 2:00 PM Pacific Time, with a live webcast available on the investor‑relations website. Analysts expect the release to shed light on revenue growth, profitability, and customer acquisition trends, and i...

Full article

RingCentral, Inc. (NYSE: RNG) was named a Top Provider in Metrigy Research’s 2025 MetriStar UCaaS Report. The company earned the highest overall customer sentiment score and performed above average in voice quality, security, value, analytics, AI capabilities, and ease of use. Customers reported the highest productivity improvements, the highest re...

Full article

In comparison, Paymentus (PAY) and Insulet (PODD) have posted robust sales growth and profitability. Paymentus’s market share has expanded, while Insulet’s free cash‑flow margin has increased by 32.6 percentage points over the past five years, offering attractive investment prospects relative to their peers.

Full article

DoubleVerify (DV) is a cash‑rich firm with a trailing 12‑month free cash‑flow margin of 19.2 %. Its sales growth is projected to slow to 9.3 % over the next 12 months as competitive pressure and higher spending on sales and marketing erode operating margins. DV’s forward price‑to‑sales ratio remains high at 2×. Despite these headwinds, its stock pr...

Full article

Leerink notes that Moderna’s strengthened solvency could intensify the IP dispute, leaving legal and royalty outcomes as a continuing risk. Consequently, analysts focus on the 2026 batoclimab catalyst as the central lever for potential upside. The long‑term revenue growth and net profit margin inputs remain unchanged, while the projected future P/E...

Full article

Roivant Sciences’ valuation model remains anchored at a $27.0 per‑share fair value, but the required return has risen to a discount rate of 7.54%, tightening the price target narrative. The shift follows the rescheduling of batoclimab Phase 3 readouts to 2026 and the persistence of litigation over Moderna royalties. Analysts such as Citi’s Samantha...

Full article

Encompass Health (EHC) shares surged after the company reported fourth‑quarter results that beat Wall Street expectations and issued 2026 earnings and revenue guidance above prior analyst forecasts. The stock has posted a 1‑year total shareholder return of 6.21%, a 3‑year return of 75.81%, and a 5‑year return of 69.80%. In the short term, share pri...

Full article

Carlyle Group’s Q4 2025 results highlighted a mixed performance: revenue and net income fell short of the prior year, yet the firm posted record fee‑related earnings driven by strong activity on its Global Credit and AlpInvest platforms. Fund‑raising inflows were robust, with the firm attracting new commitments that offset the dip in earnings.

Full article

CFT remains one of the world’s largest interdealer brokers, operating in over 30 countries with more than 2,500 employees. The Group offers broking and data services across a full spectrum of financial products, including money‑market products, bonds, interest‑rate, currency and credit derivatives, equities, equity derivatives, interest‑rate future...

Full article

In the fourth quarter of 2025, revenue grew 11.7 % at constant exchange rates, reaching CHF 293.2 million compared with CHF 283.5 million in the same period of 2024. Both the interdealer broking (IDB) business and retail (Non‑IDB) segments supplied the growth.

Full article